# Orbis Medicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/orbis-medicines-aps

- Industry: Biotechnology
- Headquarters: Frederiksberg, Denmark
- Website: www.orbismedicines.com/
- Total disclosed funding: $121M
- Latest round: Series A (Jan 6, 2025)
- Investors on record: 5

## About

Based in Copenhagen, Denmark, and founded in 2021 by co-founders Chrisitan Heinis and Sevan Habeshian, Orbis Medicines ApS operates as a provider of macrocycle drug development solutions with a focus on oral alternatives to blockbuster biologic drugs and other therapies. In February 2024, Orbis Medicines ApS raised DKK 193.78 million in seed funding co-led by Novo Holdings and Forbion. In January 6, 2025, Orbis Medicines raised EUR 90 million Series A funding round led by New Enterprise Associates, with participation from Forbion, Novo Holdings, Cormorant Asset Management, and Lilly Ventures.

The company provides a drug discovery platform called nGen that explores the macrocycle chemical space to create oral macrocycle candidates (nCycles) for intra- and extracellular targeting. Additionally, the firm offers high-throughput chemical synthesis and large-scale assaying services to support drug development efforts.

## Funding rounds

- Series A, Jan 6, 2025, $93M — New Enterprise Associates, Lilly Ventures, Novo Holdings, Forbion, Cormorant Asset Management
- Seed, Feb 29, 2024, $28M — Forbion, Novo Holdings

## Investors

- Forbion (https://capitalatlas.ai/funds/forbion) — Seed, Series A
- Novo Holdings — Seed, Series A
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series A
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A